Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.
Byoung Chul Cho, MD, PhD
Advertisement
Articles by Byoung Chul Cho, MD, PhD
Byoung Chul Cho, MD, PhD, discusses key findings from the phase 3 MARIPOSA study of first-line amivantamab plus lazertinib vs osimertinib in EGFR-mutant locally advanced or metastatic non– small cell lung cancer.
Advertisement
Latest Updated Articles
Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLCPublished: June 1st 2024 | Updated:
Dr Cho on First-Line Amivantamab Plus Lazertinib in EGFR-Mutant NSCLCPublished: October 23rd 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5